Land: Singapore
Språk: engelsk
Kilde: HSA (Health Sciences Authority)
ONDANSETRON HCl DIHYDRATE EQV ONDANSETRON
SANDOZ SINGAPORE PTE. LTD.
A04AA01
10 mg EQV to 8mg Ondansetron
TABLET, FILM COATED
ONDANSETRON HCl DIHYDRATE EQV ONDANSETRON 8 mg
ORAL
Prescription Only
Aspen Bad Oldesloe GmbH
ACTIVE
1990-10-16
ZOFRAN™ TABLETS ONDANSETRON HYDROCHLORIDE DIHYDRATE QUALITATIVE AND QUANTITATIVE COMPOSITION _ZOFRAN_ tablets 8 mg: Each tablet contains ondansetron 8 mg as hydrochloride dihydrate. PHARMACEUTICAL FORM _ZOFRAN_ tablets 8 mg: Yellow, oval, film-coated tablet engraved with ‘GXET5’ on one face and plain on the other face. CLINICAL PARTICULARS INDICATIONS ADULTS _ZOFRAN_ oral formulations are indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. _ZOFRAN_ is also indicated for the prevention of post-operative nausea and vomiting. PAEDIATRIC POPULATION INJECTION AND ORAL FORMULATIONS: _ZOFRAN_ is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy. No studies have been conducted on the use of orally administered ondansetron in the prevention or treatment of post-operative nausea and vomiting; IV injection is recommended for this purpose. DOSAGE AND ADMINISTRATION _ZOFRAN_ is available for oral and parenteral use to allow the route of administration and dosing to be flexible. CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING (CINV AND RINV) The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The selection of dose regimen should be determined by the severity of the emetogenic challenge. • ADULTS EMETOGENIC CHEMOTHERAPY AND RADIOTHERAPY The recommended oral dose is 8 mg taken 1 to 2 hours before chemotherapy or radiation treatment, followed by 8 mg orally every 12 hours later _ _ for a maximum of 5 days. To protect against delayed or prolonged emesis after the first 24 hours, oral treatment with _ZOFRAN_ should be continued for up to 5 days after a course o Les hele dokumentet
Page 1 of 13 TRADE NAME Zofran TM DESCRIPTION AND COMPOSITION PHARMACEUTICAL FORM _ _ _ZOFRAN_ tablets 8 mg: Yellow, oval, film-coated tablet engraved with ‘GXET5’ on one face and plain on the other face. Each tablet contains ondansetron 8 mg as hydrochloride dihydrate. ACTIVE SUBSTANCE Ondansetron EXCIPIENTS _ _ Lactose Microcrystalline cellulose Pregelatinised maize starch Magnesium stearate Methyl hydroxypropylcellulose Titanium dioxide (E171) Iron oxide (E172) INDICATIONS ADULTS _ZOFRAN_ oral formulations are indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. _ZOFRAN_ is also indicated for the prevention of post-operative nausea and vomiting. PAEDIATRIC POPULATION_ _ _ZOFRAN_ is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy. No studies have been conducted on the use of orally administered ondansetron in the prevention or treatment of post-operative nausea and vomiting; IV injection is recommended for this purpose. DOSAGE REGIMEN AND ADMINISTRATION Page 2 of 13 DOSING REGIMEN CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING (CINV AND RINV) The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The selection of dose regimen should be determined by the severity of the emetogenic challenge. ADULTS EMETOGENIC CHEMOTHERAPY AND RADIOTHERAPY The recommended oral dose is 8 mg taken 1 to 2 hours before chemotherapy or radiation treatment, followed by 8 mg orally every 12 hours later _ _ for a maximum of 5 days. To protect against delayed or prolonged emesis after the first 24 hours, oral treatment with _ZOFRAN_ should be continued for up to 5 days after a course of treatment. The recommended oral dose is 8 mg to be taken twice daily. HIGHLY EMETOGENIC CHEMOTHERAPY E.G. HIGH-DOSE CISPLATIN _ZOFRAN_ can be given by oral, intravenous (IV), or intramuscular (IM) administration. _ZOFRAN_ has been shown to be equally effective in the fol Les hele dokumentet